

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 43/04, 63/00, C12N 13/00, 5/00	A1	(11) International Publication Number: WO 99/18792 (43) International Publication Date: 22 April 1999 (22.04.99)
(21) International Application Number: PCT/US98/21354 (22) International Filing Date: 8 October 1998 (08.10.98) (30) Priority Data: 60/062,018 10 October 1997 (10.10.97) US (71) Applicant: JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US). (71)(72) Applicants and Inventors: LAWRENCE, John, H., III [US/US]; 8 Woodward Court, Reisterstown, MD 21136 (US). DONAHUE, Kevin, J. [US/US]; Apartment A, 935 N. Calvert Street, Baltimore, MD 21205 (US). (74) Agents: CORLESS, Peter, F. et al.; Dike, Bronstein, Roberts & Cushman, 130 Water Street, Boston, MA 02109 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: GENE DELIVERY COMPOSITIONS AND METHODS (57) Abstract The present provides methods and compositions that enable effective delivery of nucleic acids to desired cells, including to a solid organ such as a mammalian heart. The methods and compositions enable effective gene transfer and subsequent expression to a majority of cells throughout a solid organ such as the heart. Methods and compositions of the invention preferably provide enhanced vascular permeability that enables increased gene transfer to targeted cells, but without significant degradation or injury to endothelial cell layers. Global delivery of nucleic acid to an intact heart has been achieved with as little as 2 minutes of intracoronary exposure to the administered nucleic acid.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	IS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

GENE DELIVERY COMPOSITIONS AND METHODS

BACKGROUND OF THE INVENTION

1. Field of the invention.

The present invention relates to improved gene transfer methods and, more particularly, methods that enable highly efficient and widespread delivery of selected
5 nucleic acids, to solid organs such as the heart or liver as well as to other solid cell masses such as a solid tumor.

2. Background.

Effective delivery of nucleic acid to cells or tissue with high levels of expression are continued goals of gene transfer technology. As a consequence of the
10 general inability to achieve those goals to date, however, clinical use of gene transfer methods has been limited.

Thus, for example, several delivery schemes have been explored for *in vivo* myocardial gene transfer, but none has proven capable of modifying a majority of cardiac myocytes in a homogeneous fashion. Techniques involving injection directly
15 into the myocardium are considered of limited use because gene expression does not extend significantly beyond the needle track. R. J. Guzman et al. *Circ Res* 1993; 73:1202-1207; A. Kass-Eisler *Proc Natl Acad Sci* 1993; 90:11498-11502. In one study, percutaneous intracoronary delivery of 10^{10} pfu of adenovirus caused infection in only about one-third of the myocytes in the region served by the target artery. E. Barr et al.
20 *Gene Therapy* 1994, 1:51-58.

Other coronary delivery models, either *in situ* or *ex vivo*, have produced a very small percentage of infected cells spread throughout the heart. J. Muhlhauser et al. *Gene Therapy* 1996; 3:145-153; J. Wang et al. *Transplantation* 1996; 61:1726-1729. To date, no *in vivo* delivery system has been able to infect a majority of cells in an
25 intact heart.

Certain gene delivery procedures also have been quite invasive and hence undesirable. For example, one report describes essentially complete loss of

-2-

endothelium by mechanical or proteolytic means to enable gene transfer from blood vessels to cells positioned across interposing endothelial layers. See WO 93/00051.

Certain gene transfer applications also have been explored in other organs such as the liver. In particular, *ex vivo* strategies have included surgical removal of
5 selected liver cells, genetic transfer to the cells in culture and then reimplantation of the transformed cells. See M. Grossman et al., *Nat Genet* 1994, 6:335-341. Such an *ex vivo* approach, however, suffers from a number of drawbacks including, for example, the required hepatocyte transplantation. M.A. Kay et al., *Science* 1993, 262:117-119; and S.E. Raper et al., *Cell Transplant* 1993, 2:381-400. *In vivo* strategies for gene
10 transfer to the liver also have been investigated, but have suffered from low delivery efficiencies as well as low specificity to the targeted tissue. N. Ferry et al., *Proc Natl Acad Sci USA* 1991, 88:8377-8391; A. Lieber et al. *Proc Natl Acad Sci USA* 1995, 6:6230-6214; A.L. Vahrmeijer et al., *Reg Cancer Treat* 1995, 8:25-31. See also P. Heikkilä et al., *Gene Ther* 1996, 3(1):21-27.

15 Gene transfer has been generally unsuccessful in additional applications. For example, gene transfer therapies for treatment of cystic fibrosis have largely failed because transduction of insufficient numbers of cells.

It thus would be desirable to have improved methods and systems to effectively deliver nucleic acid to targeted cells and tissue. It would be particularly
20 desirable to have new methods and systems for effective delivery of nucleic acids into solid organs, especially the heart, liver, lung and the like, as well as other solid cell masses such as a solid tumor.

SUMMARY OF THE INVENTION

We have now found methods and compositions that enable effective delivery
25 of nucleic acids to desired cells, including to a solid mass of cells, particularly a solid organ such as a mammalian heart, liver, kidney, skeletal muscle, spleen or prostate, or to malignant cells such as a solid tumor. These methods and compositions enable effective gene transfer and subsequent expression of a desired gene product to a majority of cells throughout a solid cell mass, and/or gene transfer and subsequent
30 expression of a desired gene product to a solid cell mass in a desired percentage of total cells of the mass, including up to nearly 100% of targeted cells of the mass. For example, using methods and compositions of the invention, greater than 90 percent of

total cardiac myocytes showed expression of nucleic acid that was perfused for two minutes through an intact rabbit heart.

Methods and compositions of the invention preferably provide enhanced vascular permeability that enables increased nucleic acid delivery to targeted cells.

5 While not being bound by theory, it is believed these methods and compositions of the invention induce transient permeability or interruption of endothelial layers to thereby enhance gene transfer efficiency. This is distinguished from prior approaches that significantly degraded or injured endothelial cell layers in attempts to administer nucleic acid.

10 Such enhanced permeability can be readily accomplished by one of several alternative approaches, or by a combination of strategies. A preferred approach provides for use of a vasculature permeability agent. As demonstrated in the Examples which follow, use of a suitable permeability agent significantly enhances transfer of administered nucleic acid to targeted cells. A permeability agent suitably
15 may be administered through the vasculature of targeted tissue prior to administration of nucleic acid, and/or the permeability agent and exogenous nucleic acid can be administered simultaneously. Preferably, the vasculature of targeted tissue is pre-treated with a permeability agent.

Preferred vasculature permeability agents include serotonin and bradykinin.
20 Other suitable permeability agents will include platelet-activating factor (PAF), prostaglandin E₁ (PGE₁), histamine, vascular endothelium growth factor (VEGF), zona occludens toxin (ZOT), interleukin-2 and other plasma kinins in addition to bradykinin. Nitric oxide inhibitors, e.g. L-N-monomethyl arginine (L-NMMA) and L-N-nitro-arginine methyl ester (L-NAME), also can provide suitable results,
25 although these agents may be less preferred than others such as serotonin and bradykinin. Other suitable agents can be readily identified, e.g. simply by testing a candidate permeability agent to determine if it enhances uptake of nucleic acid by targeted tissue relative to a control tissue sample that has not been exposed to the candidate permeability agent. A single or a combination of more than one distinct
30 permeability agents may be administered in a particular application. In this regard, a particular application can be optimized by selection of an optimal permeability agent, or optimal "cocktail" of multiple permeability agents. Such optional agent(s) can be

readily identified by those skilled in the art by routine procedures, e.g. testing selected permeability agents and combinations thereof in *in vivo* assays.

Low extracellular calcium ion concentration conditions also can be used to enhance vascular permeability. It has been found that transfer of administered nucleic acid to targeted cells is substantially enhanced under such conditions, which also is demonstrated in the Examples which follow. Low calcium concentration conditions may be readily provided, particularly by perfusing a low calcium ion concentration fluid through the vasculature of the tissue to which nucleic acid is administered. Suitable perfusate calcium ion concentrations may range from about 40 or 50 $\mu\text{mol/L}$ to about 500 $\mu\text{mol/L}$, more preferably from about 50 $\mu\text{mol/L}$ to about 200 $\mu\text{mol/L}$. A perfusate calcium concentration of about 50 $\mu\text{mol/L}$ is particularly preferred. Calcium ion (e.g. Ca^{2+}) concentration also can be lowered through use of a suitable buffer such as a chelating agent, e.g. ethylenebis(oxyethylenitrilo)tetracetic acid (EGTA), ethylenediaminetetracetic acid (EDTA), or 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA).

Additionally, while a low calcium ion concentration can enhance nucleic acid uptake, it is also important that a minimal calcium concentration be maintained during the gene transfer protocol, at least in many or some applications. If calcium-free or essentially calcium-free conditions (e.g. perfusate calcium ion concentration of about 10-20 $\mu\text{mol/L}$ or less) are employed, cell calcium channel selectivity may be destroyed which can result in cell death upon return to physiological calcium levels, particularly in the case of administration to myocytes.

We have also found that combined use of a vasculature permeability agent and low calcium ion concentration conditions appears to provide synergistic results with higher gene transfer efficiency than that provided with either use of a permeability agent without a lowered calcium concentration, or low calcium concentration conditions in the absence of a permeability agent. Thus, as discussed above and demonstrated in the Examples which follow, greater than 90 percent of rabbit total cardiac myocytes showed expression of nucleic acid that was perfused for two minutes through an intact rabbit heart under low calcium ion concentration conditions and treatment with a permeability agent.

We also have found that certain administration conditions in addition to those discussed above also will impact efficiency of nucleic acid uptake by targeted tissue. In particular, concentration, amount and exposure time of the administered nucleic acid and temperature of the targeted tissue all can effect the rate of gene transfer.

5 Flow rate and perfusion pressure also can effect the rate of gene transfer.

More specifically, in a perfusion administration protocol, the rate of gene transfer increases with increase in concentration, total amount and exposure time of the administered nucleic acid in a perfusate. High concentration of nucleic acid in a perfusate especially can increase gene transfer rate. Preferred perfusate concentrations
10 can vary with a number of factors including the particular organ or cell mass being treated, the particular cloning vehicle being administered and the like. However, in general, preferred concentrations of a viral vector in an administered perfusate are about 1×10^8 pfu/ml or greater, more preferably a concentration of about 5×10^8 pfu/ml or greater. Administered perfusate also preferably may be recirculated and
15 readministered to a subject, e.g. to limit the total viral burden introduced into the target, or if the administered agent is in short supply. However, effective gene transfer can be achieved without recirculation, particularly if other delivery parameters are optimized. Increases in either flow rate of perfusate pressure generally will increase gene transfer efficiency, although for clinical safety it can be desirable to
20 limit both perfusate pressure and flow rate.

The rate of gene transfer also decreases with decreased temperature of targeted tissue, particularly where the tissue is below about 20°C. Delivery of the nucleic acid near body temperature of the subject is preferred, e.g. where the nucleic acid is administered at a temperature of from about 28-45°C, more preferably from about 34-
25 40°C. However, gene transfer can be achieved over wide temperature ranges, e.g. at about 4°C. Clinical circumstances may require lower temperatures, e.g. with gene transfer during cardiac surgery.

Nucleic acid administered in accordance with the invention can express a desired therapeutic agent, or may inhibit expression or function of an endogenous
30 gene of a subject. Nucleic acid also may be administered for diagnostic purposes, for example to express a marker protein. In addition to such therapeutic and diagnostic methods, methods and compositions of the invention also may be employed to

examine the effect of a heterologous gene on an intact organ such as a subject's heart, to create animal models of disease and to provide mechanistic information regarding various disease states.

In a preferred aspect, the invention includes methods for xenotransplantation.

5 Thus, for example, cells of xenogeneic tissue, particularly cells of a xenogeneic solid cells mass, can be administered exogenous nucleic acid under enhanced vascular permeability as described herein. Those cells containing exogenous nucleic acid then may be transplanted into a subject. More particularly, the exogenous nucleic acid can be administered *in vivo* or *ex vivo* to donors cells or organs, e.g. a xenogeneic heart,
10 liver, spleen and the like, in accordance with the invention and the donor cells or organ can be transplanted to a selected host, e.g. a mammal, particularly a primate such as a human. Suitable donor organs may be obtained from e.g. another primate, or a swine, particularly a pig. A variety of exogenous nucleic acids can be administered to the donor cells. For instance, nucleic acids can be administered that
15 will express a gene product that can promote a desired phenotypic characteristic. Exemplary gene products include those which can reduce immune system recognition of the xenotransplanted cells.

In another aspect, the invention includes vasculature permeability and gene transfer solutions useful in the methods of the invention. Such solutions in general
20 will be formulated to provide enhanced permeability to treated tissue upon administration of nucleic acid to such layers. Thus, suitable permeability agents will include one or more permeability agents as disclosed herein, or otherwise may be formulated to enhance permeability such as a low calcium ion concentration solution as described herein. A solution of the invention also may contain one or more
25 therapeutic agents, e.g. one or more exogenous nucleic acids (e.g. one or more recombinant adenoviruses) to be administered to a subject, or other pharmaceutical agent such as nitroglycerine to control vasospasms and the like to a solution that will be administered to a heart. A permeability or gene transfer solution may suitably contain nucleic acid in a form for administration e.g. in a suitable cloning vehicle such
30 as a viral vector dissolved in desired pharmaceutically acceptable carrier e.g. Krebs solution or other buffered solution. A permeability or gene transfer solution of the invention preferably will be pharmaceutically acceptable, e.g. sterile and otherwise

-7-

suitable for administration to a subject. Typically a vasculature permeability or gene transfer solution will be stored in a sealed (preferably, hermetically sealed) container prior to use. A permeability or gene transfer solution preferably will contain active ingredients (i.e., permeability agent, calcium ion concentration, nucleic acid) in
5 optimal dosage quantities. Solutions of the invention may suitably have other agents such as various buffers, sugars, salts and the like.

A wide variety of cells may be treated in accordance with the invention. Suitable cells for administration include those that have a distinct circulation, or circulation that can be isolated in some manner. Thus, for example, organs and other
10 cell masses are suitable for administration in accordance with the invention including e.g. heart, lung, liver, kidney, prostate, testes, ovaries, skeletal muscle, kidneys, brain, spleen and solid tumors. Exemplary tumors that can be treated in accordance with the invention include e.g. cancers of the lung, prostate, liver, brain, testes or ovaries. Cells treated in accordance with the invention may be in either a healthy or
15 diseased state. A wide variety of subjects also may be treated in accordance with the invention. Typical subjects include mammals, particularly primates, especially humans.

Other aspects of the invention are discussed below.

BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1A shows schematically a perfusion catheter suitable for *in vivo* nucleic acid administration to a heart in accordance with the invention.'

Figure 1B shows schematically an alternate catheter suitable for *in vivo* nucleic acid administration to a heart in accordance with the invention.

25 Figure 2 shows schematically an *ex vivo* cardiac perfusion system in accordance with the invention.

Figure 3 shows a comparison of the time course of adenovirus infection at two virus concentrations.

Figure 4 shows effects on adenovirus infection after pretreatment with selected vasculature permeability agents.

30 Figure 5 shows infection rates at selected exposure times after pretreatment with a preferred vasculature permeability agent and under low calcium concentration conditions.

DETAILED DESCRIPTION OF THE INVENTION

As stated above, the present invention provides methods and compositions that enable effective delivery of nucleic acid to desired cells, including to cells of a solid cell mass, e.g. of an organ such as a mammalian heart or liver, or other solid cell mass
5 such as a solid tumor.

Preferably, the methods and compositions of the invention provide enhanced microvascular permeability that enables increased gene transfer to targeted cells. As discussed above, these methods and compositions create transient permeability of endothelial layers, and preferably without significant degradation or injury to
10 endothelial cell layers of a solid cell mass, although some transient disruption of the endothelial layer may occur.

As used herein, the term "without significant degradation or injury to endothelial cell layers" or other similar phrase means that less than 25%, more typically less than 15 or 10 percent, of endothelial cells are lost from the treated vessel
15 wall prior to administration of nucleic acid to a subject. This contrasts from denuding and consequent injury of the endothelium through mechanical trauma or use of proteolytic enzymes which would result through use of prior methods. Lack of significant degradation of endothelial cell layers can be readily determined, e.g. by microscopic examination of the layer. Also, lack of significant degradation of
20 endothelial cell layers can be determined by simple testing. For example, an endothelial layer can be tested to determine whether the layer has maintained a particular function and therefore is significantly degraded, e.g. a layer's ability to exhibit a reversible vasodilator response to 10^{-7} mol/L acetylcholine.

As discussed above, a wide variety of agents will be suitable as permeability
25 agents in accordance with the invention, and that suitably of a particular candidate permeability agent can be readily evaluated by testing the agent to determine if the candidate agent enhances uptake of nucleic acid by targeted tissue relative to a control tissue sample that has not been exposed to the candidate permeability agent. For example, a candidate permeability suitably may provide at least about 10, 20, 30, 40,
30 50, 60, 70, 80 or 90 percent greater uptake of nucleic acid by targeted tissue relative to a control tissue sample that has not been exposed to the candidate permeability agent. In certain applications, use of a permeability agent having even greater uptake of

nucleic acid may be preferred, e.g. where the permeability agent provides at least about 100, 125, 150, 175, 200, 300, 400, 500, 600, 800 or 1000 percent greater uptake of nucleic acid by targeted tissue relative to a control tissue sample that has not been exposed to the permeability agent. It also should be appreciated that the level of
5 nucleic agent uptake that will be suitable for various applications can differ. Thus, for certain applications, lower levels of nucleic acid uptake (e.g. nucleic acid uptake in 2% of cells in a target organ or mass of cells) may be suitable for one application, whereas for other applications, higher levels of nucleic acid uptake (e.g. nucleic acid uptake approaching 90 or 100% of cells in a target organ or mass of cells) may be
10 optimal. The conditions herein described enable graded levels of nucleic acid uptake, e.g. by appropriate varying of type and quantity of permeability agent, virus amount or concentration, and virus exposure time.

Suitable permeability agents generally will exhibit good activity in a standard *in vitro* vasculature permeability assay. For example, permeability agents preferred
15 for at least many applications will include those compounds that exhibit at least about 5%, more preferably at least about 10%, still more preferably at least about 25% or 50% of the permeability activity exhibited by an equivalent molar concentration of bradykinin in a standard vasculature permeability assay, specifically the assay disclosed in R.J. Mullins et al., *Journal of Trauma* 1989, 29(6):1053-1063. That
20 disclosed assay includes measuring skin lymph flow (LYM FLOW $\mu\text{l}/\text{min}$) after perfusing a solution containing the permeability agent through specified vasculature of a test animal for a specified period of time. References herein to a standard permeability assay are intended to refer to that protocol and as disclosed in R.J. Mullins, *supra*.

25 It also should be appreciated that optimal permeability agents and conditions for a particular application may vary with a number of factors such as the specific nucleic acid being administered, the solid cell mass that is being treated and the like. Thus, while histamine may be suitable for many applications of the invention, histamine may be less suitable for certain applications and is excluded from certain
30 aspects of the invention. Again, the suitability of any particular agent can be readily determined by simple testing as discussed above.

Nucleic acid administered in accordance with the invention may be any nucleic acid (DNA or RNA) including genomic DNA, cDNA, rRNA, mRNA and tRNA. These constructs may encode a gene product of interest, e.g. a therapeutic or diagnostic agent. A wide variety of known polypeptides are known that may be
5 suitably administered to a patient in accordance with the invention.

For instance, for administration to cardiac myocytes, nucleic acids that encode vasoactive factors may be employed to treat vasoconstriction or vasospasm. Nucleic acids that encode angiogenic growth factors may be employed to promote revascularization. Suitable angiogenic growth factors include e.g. the fibroblast
10 growth factor (FGF) family, endothelial cell growth factor (ECGF) and vascular endothelial growth factor (VEGF; see U.S. Patents 5,332,671 and 5,219,739). See Yanagisawa-Miwa et al., *Science* 1992, 257:1401-1403; Pu et al., *J Surg Res* 1993, 54:575-83; and Takeshita et al., *Circulation* 1994, 90:228-234. Additional agents that may be administered to ischemic heart conditions, or other ischemic organs include
15 e.g. nucleic acids encoding transforming growth factor α (TGF- α), transforming growth factor β (TGF- β), tumor necrosis factor α and tumor necrosis factor β . Suitable vasoactive factors that can be administered in accordance with the invention include e.g. atrial natriuretic factor, platelet-derived growth factor, endothelin and the like. Additional agents that may be administered for the prevention of atrial or
20 ventricular arrhythmias include ion channel proteins and/or functionally effective subunits and/or fragments of ion channel proteins that can function to either overexpress or inhibit certain ion currents in the hearts. Further regulatory sequences, such as promoter elements may be added to restrict expression to specific regions of an organ, such as the heart (e.g., atrial natriuretic factor promoter produces
25 preferential expression in the atria relative to the ventricles). Alternatively, regulatory sequences may be added so that expression is regulated up or down by an administered or endogenous compound, such as a hormone.

For treatment of malignancies, particularly solid tumors, nucleic acids encoding various anticancer agents can be employed, such as nucleic acids that code
30 for diphtheria toxin, thymidine kinase, pertussis toxin, cholera toxin and the like. Nucleic acids encoding antiangiogenic agents such as matrix metalloproteases and the like also can be employed. See J.M. Ray et al. *Eur Respir J* 1994, 7:2062-2072.

- 11 -

For other therapeutic applications, polypeptides transcribed by the administered nucleic acid can include growth factors or other regulatory proteins, a membrane receptor, a structural protein, an enzyme, a hormone and the like.

Also, as mentioned above, the invention provides for inhibiting expression or
5 function of an endogenous gene of a subject. This can be accomplished by several alternative approaches. For example, antisense nucleic acid may be administered to a subject in accordance with the invention. Typically, such antisense nucleic acids will be complementary to the mRNA of the targeted endogenous gene to be suppressed, or to the nucleic acid that codes for the reverse complement of the endogenous gene.
10 See J.H. Izant et al., *Science* 1985, 229:345-352; and L.J. Maher II et al., *Arch Biochem Biophys* 1987, 253:214-220. Antisense modulation of expression of a targeted endogenous gene can include antisense nucleic acid operably linked to gene regulatory sequences.

Alternatively, nucleic acid may be administered which antagonizes the
15 expression of selected endogenous genes (e.g. ribozymes), or otherwise interferes with function of the endogenous gene or gene product.

The nucleic acid to be administered can be obtained by known methods, e.g. by isolating the nucleic acids from natural sources or by known synthetic methods such as the phosphate triester method. See, for example, *Oligonucleotide Synthesis*,
20 IRL Press (M.J. Gait, ed. 1984). Synthetic oligonucleotides also may be prepared using commercially available automated oligonucleotide synthesizers. Also, as is known, if the nucleic acid to be administered is mRNA, it can be readily prepared from the corresponding DNA, e.g. utilizing phage RNA polymerases T3, T7 or SP6 to prepare mRNA from the DNA in the presence of ribonucleoside triphosphates. The
25 nucleotide sequence of numerous therapeutic and diagnostic peptides including those discussed above are disclosed in the literature and computer databases (e.g., GenBank, EMBL and Swiss-Prot). Based on such information, a DNA segment may be chemically synthesized or may be obtained by other known routine procedures such as PCR.

30 To facilitate manipulation and handling of the nucleic acid to be administered, the nucleic acid is preferably inserted into a cassette where it is operably linked to a promoter. The promoter should be capable of driving expression in the desired cells.

The selection of appropriate promoters can be readily accomplished. For some applications, a high expression promoter is preferred such as the 763-base pair cytomegalovirus (CMV) promoter. The Rous sarcoma (RSV) (Davis et al., *Hum Gene Ther*, 1993, 4:151) and MMT promoters also may be suitable. Additionally, 5 certain proteins can be expressed using their native promoter. Promoters that are specific for selected cells also may be employed to limit transcription in desired cells. Other elements that can enhance expression also can be included such as an enhancer or a system that results in high expression levels such as a *tat* gene or a *tar* element. A cloning vehicle also may be designed with selective receptor binding and using the 10 promoter to provide temporal or situational control of expression.

The cassette then can be inserted into a vector, e.g. a viral vector such as adenoviruses, adeno-associated virus, retroviruses, herpes viruses (e.g. herpes simplex virus), vaccina viruses, papoviruses, the Sendai virus, the SV40 virus, hybrid viruses, and the like. As mentioned above, adenoviruses are generally preferred. Lytic and 15 semi-lytic viral vectors also can be employed, particularly for administration to malignant cells, such as cells of a solid tumor. Replication-defective recombinant adenoviral vectors, and other suitable vectors, can be produced by known procedures. See Quantin et al., *Proc Natl Acad Sci USA* 1992, 89:2581-2584; Stratford-Perricadet et al., *J. Clin. Invest.* 1992, 90:626-630; and Rosenfeld et al., *Cell* 1992, 68:143-155. 20 The vector also may contain a selectable marker, for instance β -galactosidase (β -gal) or GFP as employed in the Examples which follow. In general, preparation of vector containing desired nucleic acid for administration to a subject is in accordance with known procedures as disclosed e.g. in *Molecular Cloning, A Laboratory Manual* (2d ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor 1989); *Current Protocols in* 25 *Molecular Biology*, (eds. Ausubel et al., Greene Publ. Assoc., Wiley-Interscience, NY, NY 1992); and *Methods in molecular biology* (ed. EJ Murray, Humana, Clifton, NJ 1991). See also the Examples which follow for exemplary procedures.

Naked nucleic acid also may be administered in accordance with the invention, typically formulated with a pharmaceutically acceptable carrier. For example, a 30 polynucleotide, optionally present as a pharmaceutically acceptable salt, can be present in forms such as suspensions, solutions, emulsions in oily or preferably aqueous vehicles that are preferably sterile and pyrogen-free. Pharmaceutically

acceptable salts can be suitably prepared from organic or inorganic bases, such as a sodium or potassium salt, or a salt of a primary, secondary or tertiary amine. The administration solution can suitably contain buffers to adjust the pH of the solution, nonionic materials such as sugars e.g. sucrose to adjust tonicity.

5 Nucleic acid also may be administered as DNA-liposome or RNA-liposome complexes. Such complexes comprise a mixture of fat particles or lipids which bind to DNA or RNA to provide a hydrophobic coated delivery vehicle. Suitable liposomes may comprise any of the conventional synthetic or natural phospholipid liposome materials including phospholipids from natural sources such as egg, plant or
10 animal sources such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, sphingomyelin, phosphatidylserine or phosphatidylinositol. Synthetic phospholipids also may be used e.g., dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dioleoylphosphatidylcholine and corresponding synthetic phosphatidylethanolamines and phosphatidylglycerols. Cholesterol or other sterols,
15 cholesterol hemisuccinate, glycolipids, 1,2-bis(oleoyloxy)-3-(trimethyl ammonio)propane (DOTAP), N-[1-(2,3-dioleoyl)propyl]-N,N,N-trimethylammonium chloride (DOTMA), and other cationic lipids may be incorporated into the liposomes.

Typical subjects to which nucleic acid will be administered for therapeutic application include mammals, particularly primates, especially humans, and subjects
20 for xenotransplant applications such as a primate or swine, especially pigs. For veterinary applications, a wide variety of subjects will be suitable, e.g. livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys and the like; and pets such as dogs and cats. For diagnostic or research applications, a wide variety of mammals will be suitable subjects including rodents
25 (e.g. mice, rats, hamsters), rabbits, primates, and swine such as inbred pigs and the like.

The effective dose of nucleic acid will be a function of the particular expressed protein, the target tissue, the subject (including species, weight, sex, general health, etc.) and the subject's clinical condition. The effective dose of nucleic acid also will
30 be a function of the permeability cocktail, which generally will allow less total viral particles to be delivered. Optimal administration rates for a given protocol of administration can be readily ascertained by those skilled in the art using conventional

dosage determination tests. Additionally, frequency of administration for a given therapy can vary, particularly with the time cells containing the exogenous nucleic acid continue to produce the desired polypeptide as will be appreciated by those skilled in the art. Also, in certain therapies, it may be desirable to employ two or
5 more different proteins to optimize therapeutic results.

Nucleic acid can be administered to selected tissue by a variety of protocols. The preferred administration method is perfusion of a liquid formulation of the nucleic acid through a solid organ such as a heart or liver or other solid cell mass such as a solid tumor. It may be preferred to recirculate the perfusate through the organ or
10 cell mass which, among other things, can limit delivery of the nucleic acid to targeted cells. A preferred perfusion protocol is described in the Examples which follow. See also Donahue et al., *Proc Natl Acad Sci USA* 1997, 94:4664-4668 for suitable perfusion procedures.

If an adenovirus vector is employed, the nucleic acid preferably is
15 administered in a formulation that is essentially (less than about 5 percent by volume) or completely free of red blood cells which can adsorb adenovirus. Krebs solution is a particularly preferred carrier. Preferably the liquid carrier has a low calcium ion concentration as discussed above. However, other solutions, even native bloodstream with physiologic levels of red blood cells and calcium, can be employed and may be
20 suitable for certain applications, e.g. where the primary intervention for enhancing gene transfer is alteration of vascular permeability.

The concentration of nucleic acid within a liquid carrier can vary, but relatively high concentrations are preferred to provide increase efficiency of nucleic acid uptake as discussed above. More specifically, preferably a viral vector containing
25 nucleic acid for administration is present in a liquid carrier such as Krebs solution at a concentration of about 1×10^8 plaque forming units (pfu)/ml or greater, more preferably a concentration of about or 5×10^8 , still more preferably a concentration of about 1.0×10^9 or 1.5×10^9 pfu/ml or greater.

Flow rates of a perfusate solution containing nucleic acid also can vary, but are
30 preferably relatively rapid compared to normal blood flow in the delivery vessel to provide enhanced nucleic acid uptake. For example, a perfusate flow rate of at least about 5, 10, 15, 20, 25, 50 or 75 percent more rapid compared to normal blood flow in

the delivery vessel can be employed. In certain applications, even more rapid flow rates will be preferred, e.g. a perfusate flow rate of at least about 100, 200, 300, 400 or 500 percent more rapid compared to normal blood flow. Flow rates up to 600, 700, 800, 900 or 1000 percent more rapid compared to normal blood flow rate of a subject
5 also can be suitable for certain applications.

It should be appreciated that a particular application of the invention can be readily optimized, e.g. the optimal permeability agents readily selected as discussed above by simple testing against a control; the use of lowered calcium conditions can be readily assessed by testing relative to a control; perfusate flow rates, perfusate
10 concentrations of nucleic acids and the like also all can be readily optimized by testing relative to a control. Optimal conditions and agents may vary from application to application, e.g. for administration to varying organs or mammals of different species.

Nucleic acid can be administered by perfusion by a variety of strategies. Thus, for instance, for an *in vivo* administration, a catheter delivery protocol can be
15 employed. Such *in situ* administration can be suitably employed in a procedure solely to deliver the nucleic acid, or in conjunction with a separate surgical procedure such as a peripheral cardiac bypass.

Figure 1A of the drawings depicts perfusion catheter 10 which can be suitably used for an *in vivo* administration. In use, catheter 10 can be inserted into selected
20 delivery vessel of a subject such as the depicted mammalian heart 12. The catheter balloon 14 that occludes blood flow, thereby preventing mixing of red blood cells with the perfusate, and defines a point at which administered perfusate enters the selected vasculature via multiple perfusion openings 16. As should be clear, the administered perfusate can be a number of compositions, such as a solution containing
25 on or more permeability agents, a low calcium ion concentration "washout" solution or a solution containing nucleic acid. The isolation provided by balloon 14 can prevent backflow of perfusate to vascular beds proximal to balloon 14. If the venous circulation is not collected, then the perfusate may spread more widely in the body. If desired, the administered solutions may be recirculated through the catheter system
30 and then readministered to the delivery vessel of the subject. Direction of flow through the catheter system is shown by the depicted arrow in Figure 1A. As is

-16-

known in the art, the catheter can be advanced to an area of treatment of a subject with a guide wire and use of radiopaque markers.

Figure 1B of the drawings depicts a further catheter 20 which also can be suitably used for an *in vivo* administration. In use, catheter 20 can be inserted into
5 selected delivery vessel 22 of a subject such as a mammalian heart. As with catheter 10, catheter balloon 24 defines a point at which administered perfusate enters the selected vasculature through end lumen or opening 26. As again with catheter 10, perfusate administered with catheter 20 can be a number of compositions, such as a solution containing one or more permeability agents, a low calcium ion concentration
10 "washout" solution or a solution containing nucleic acid. Isolation provided by balloon 24 prevents spread of the nucleic acid to other areas other than the targeted cell mass. If desired, the administered solutions may be recirculated through the catheter system and then readministered to the delivery vessel of the subject. Direction of flow through the catheter system is shown by the depicted arrow in
15 Figure 1B. Catheter 20 also can be advanced to an area of treatment of a subject with a guide wire and use of radiopaque markers.

Nucleic acid also may be suitably administered by perfusion through a procedure involving extra-corporal circulation such as performed during coronary artery bypass surgery and aortic valve replacement surgery. In such clinical settings,
20 both arterial and venous vessels can be accessed for delivery, collection and possible recirculation of the perfusate formulation thus targeting gene transfer to the heart and minimizing delivery to remote organs or tissues.

Ex vivo perfusion systems also may be employed, particularly in test animals such as a rabbit, rodent, etc. to assess viability and efficiency of specific permeability
25 agents, calcium concentration conditions, cloning vehicles, and perfusion conditions such as flow rate, amount of nucleic acid administered, concentration of nucleic acid in perfusate, etc. An *ex vivo* procedure also can be employed to deliver therapeutic procedures followed by transplanted of the organ into a patient. A suitable *ex vivo* system is shown schematically in Figure 2 of the drawings and corresponds to the
30 system employed in the Examples. As depicted in Figure 2, desired fluid 40 (e.g., fluid containing one or more permeability agents, or a calcium "washout" solution, or fluid containing the selected nucleic acid) can be circulated through line 42 and into

an explanted organ such as the depicted heart 44. Fluid 40 enters explanted organ 44 through inlet port 46, circulates through and then exits organ 44 via outlet port 48. Fluid 40 can be added or removed through the system, flow rate controlled and the like via automated delivery device 50. Nucleic acid delivery also can be achieved following placement of the balloon catheter within one of the main coronary arteries or branches of the coronary arteries.

Alternate *ex vivo* methods do not involve removal of an intact organ, but rather removal of selected tissue of an organ followed by reimplanting of the tissue after transformation of the removed cells with the desired exogenous nucleic acid. However, as discussed above, such an approach is generally less preferred for the substantial surgical intervention required and difficulty of effective grafting of genetically modified cells.

Additionally, other therapeutic agents, including non-peptide therapeutics, can be administered together with the gene product of the exogenous nucleic acid. Thus, as one example, nitroglycerine may be co-administered to control vasospasms, or an anticancer agent may be co-administered during treatment of malignant cells.

The invention also provides pharmaceutical kits for treatment of a disorder of a subject. Kits of the invention preferably include a delivery system or device to administer the exogenous nucleic acid such as a catheter as discussed above, an *ex vivo* administration system such as those discussed above, a syringe for injection administration and the like. The kits also will include the nucleic acid to be administered, preferably in a form suitable for administration, e.g. contained in a suitable cloning vehicle such as a viral vector dissolved in desired pharmaceutically acceptable carrier e.g. Krebs solution or other buffered solution that preferably has a low calcium concentration in accordance with the invention and may have other agents such as various buffers, sugars, salts and the like. Alternatively, the nucleic acid may be freeze dried and packaged separately from the fluid carrier. Preferably the nucleic acid and carrier would be present in the kit in optimal dosage quantities. A pharmaceutical kit of the invention also may contain other therapeutic agents that may be co-administered with the gene product of the exogenous gene product as discussed above.

A kit of the invention also preferably contains one or more vasculature permeability agents, packaged either separately from or admixed with a liquid formulation to perfuse the one or more agents through a selected area of a subject. The kit also may contain a calcium "washout" formulation to lower the calcium concentration to a desired level in a selected area of a subject. For example, such a "washout" solution could be Krebs solution or other fluid having a low calcium concentration in accordance with the invention and administered prior to administration of the exogenous nucleic acid as discussed above. The one or more permeability agents also may be present in the kit either packaged separately from for later formulation, or pre-formulated with such a low calcium concentration solution for administration prior to delivery of the exogenous nucleic acid. Each of the materials of a kit of the invention, or any composition of the invention that is administered to a subject, particularly a human, should be sterile and otherwise pharmaceutically acceptable. Each of the kit materials intended for administration typically will be stored in a suitable container, preferably each such container hermetically sealed. The kit also suitably may contain instructions for use and administration of the kit materials.

As discussed above, the invention also provides methods for introducing into a recipient subject transformed donor cells to express a desired gene product in the recipient. Nucleic acid is introduced into the donor cells in accordance with the invention as described herein, i.e. by enhancing vasculature permeability to introduce desired nucleic acid into the cells. Typical recipient subjects for these xenotransplant methods include those subjects disclosed above, i.e. mammals, particularly primates, preferably a human. Donor cells can come from a variety of sources such as from the sources disclosed above. Donor cells from a swine such a pig, or a primate such as a human, are generally preferred. A solid donor organ containing cells comprising exogenous nucleic acid may be transplanted into the recipient subject. Xenotransplant procedures in general have described in the literature such as in U.S. Patents 5,650,148 and 5,658,564 and the like.

All documents mentioned herein are incorporated herein by reference.
The following non-limiting examples are illustrative of the invention.

General Comments

The following materials and conditions were employed in the following Examples 1 and 2.

Adenovirus vectors. Ad β gal contained the E. coli *lac Z* gene driven by the human cytomegalovirus (CMV) immediate early promoter. Virus stocks were expanded as previously described in Graham FL, Prevec L: Manipulation of adenovirus vectors, in Murray EJ (ed): *Methods in molecular biology*. Clifton, NJ, Humana, 1991, pp 109-128, aliquoted in small volumes, and stored in phosphate-buffered saline (PBS) with 10% sucrose at -80° C. Viral titers were determined by the average of two plaque assays performed using a traditional method as described in *Methods in molecular biology, supra*.

Statistical Analysis. Unless otherwise stated, all experiments were performed in triplicate and the data are presented as mean \pm s.d. Statistical significance was determined at the 5% level using the unpaired Student's *t*-test.

Baseline conditions for the Langendorff-perfusion experiments included a coronary flow rate of 30 ml/min, and perfusion with Krebs solution containing 1.0 mmol/L Ca²⁺ and 1.0 x 10⁸ pfu/ml of Ad β gal at 37°C. All infections occurred in Krebs solution.

Example 1 - Separate use of permeability agents and low calcium concentration conditions.

Acutely explanted rabbit heart (New Zealand White; 2-3 kg total body weight) were employed for gene transfer tests of this Example 1 and the following Example 2. The rabbits received heparin anticoagulation (1000 units IV) prior to pentobarbital (50 mg/kg IV). Each heart was extracted and rinsed twice in ice-cold, modified Krebs buffer containing 138.2 mM Na⁺, 5.4 mM K⁺, 1.2 mM Mg²⁺, 1.0 mM Ca²⁺, 144.4 mM Cl⁻, 1.2 mM SO₄²⁻, 1.2 mM H₂PO₄⁻, 20 mM HEPES, and 15 mM glucose, saturated with O₂ at pH 7.4. Next, the aorta was cannulated, and the heart was suspended in an insulated chamber at 35-37°C.

Langendorff perfusion occurred by retrograde flow from the cannula in the ascending aorta to the coronary arteries. Each heart was first perfused with 20 ml Krebs buffer at approximately 30 ml/min. After initial perfusion, the heart was pretreated with one of the following: (1) 90 ml of 50 μ M calcium-Krebs over 3

-20-

minutes, or (2) 500 ml of normal Krebs buffer containing 10^{-5} M of either bradykinin or serotonin over 15 minutes.

Following pretreatment, the heart was infected with Krebs buffer containing the pretreatment supplements (i.e. low calcium, serotonin, bradykinin solutions) in the same concentrations and solutions that were employed for pretreatment, 1 mg/ml albumin and Ad β gal at specified concentrations. At the end of the infection interval, the virus-containing media was removed and the heart was perfused with virus-free Krebs buffer at a flow rate of 10-30 ml/min to maintain a total Langendorff-perfusion time of 180 minutes before perfusion with nominally calcium-free Krebs and cell isolation by proteolytic digestion. The cells were cultured for 48 hours prior to fixation and staining to detect β -galactosidase activity.

Under these conditions, it was found that less than 1% of cells were infected after 2 minutes and that the percentage increased with exposure time, saturating at 40% with 60 minute infection. Increasing the virus concentration to 1.6×10^9 pfu/ml caused an improvement in both the infection rate and the final percentage of infected cells (see Figure 3 of the drawings where results are shown; baseline conditions included infection in Krebs solution at 30 ml/min and 37°C, followed by a virus-free perfusion with Krebs solution; N=3 for each data point). The percentage of infected cells was $13.7 \pm 4.5\%$ after 10 minutes, $52.6 \pm 8.9\%$ at 20 minutes, and $95.3 \pm 0.7\%$ at 30 minutes, and $96.1 \pm 0.2\%$ after 60 minutes of virus recirculation. Each of the supplemental agents (i.e. serotonin, bradykinin and low calcium) perfused to enhance microvascular permeability caused a significant increase in the percentage of infected myocytes (see Figure 4 of the drawings where results for serotonin and bradykinin are depicted graphically). The greatest increase occurred with exposure to serotonin, causing $77.8 \pm 2.3\%$ infection. Bradykinin and low calcium pretreatment each resulted in 65-67% infection.

Example 2 - Combined use of permeability agent and low calcium concentration conditions.

The serotonin and low calcium protocols as described in Example 1 above were combined. Pretreatment was accomplished with 500 ml of normal Krebs buffer containing 10^{-5} M of serotonin over 15 minutes followed by 90 Mlles of the same reduced calcium (50 μ M) concentration solution over 3 minutes. Those same

serotonin and low calcium concentration solutions were used during delivery of the Ad β gal vector. Results are set forth below and in Figure 5 of the drawings. Those results and the results of Example 1 above indicate a synergistic increase in gene transfer efficiency resulting from the combined use of a permeability agent and low calcium concentration conditions in accordance with the invention. Virus concentration was also varied to increase gene transfer efficiency. Specifically, using a virus concentration of 1.0×10^8 pfu/ml, infection occurred in $49.4 \pm 1.0\%$ of cells after 10 minute virus exposure and $16.3 \pm 3.4\%$ of cells after 2 minutes. Then, a ten minute exposure to an Ad β gal concentration of 6.0×10^8 pfu/ml produced $91.5 \pm 4.4\%$ infection, and an Ad β gal concentration of 1.6×10^9 pfu/ml resulted in $92.3 \pm 1.0\%$ after 2 minutes of virus exposure.

The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention.

What is claimed is:

1. A method for administering nucleic acid to express a gene product in cells in tissue of interest, comprising:
treating the tissue to increase vascular permeability of exogenous nucleic acid;
and
administering exogenous nucleic acid to the tissue.
2. The method of claim 1 wherein the tissue is treated with a vascular permeability agent to increase vascular permeability.
3. The method of claim 1 or 2 wherein the nucleic acid is administered under low calcium ion concentration conditions.
4. The method of any one of claims 1-3 wherein the tissue is treated with a low calcium ion concentration solution.
5. A method for expressing a gene product in cells of tissue of interest, comprising:
treating the tissue with a vascular permeability agent under conditions of low calcium concentration to increase vascular permeability of exogenous nucleic acid;
and
administering exogenous nucleic acid to the tissue.
6. A method of any one of claims 1-5 wherein the nucleic acid is administered by perfusion.
7. The method of claim 6 wherein the perfusate of nucleic acid is recirculated and then readministered through the organ or cell mass.
8. The method of any one of claims 1-7 wherein the permeability agent is serotonin, bradykinin, platelet-activating factor, prostaglandin E₁, histamine, vascular endothelium growth factor, zona occludens toxin, interleukin-2, plasma kinins, L-N-monomethyl arginine or L-N-nitro-arginine methyl ester.
9. The method of claims 1-7 wherein the permeability agent is other than histamine.
10. The method of claims 1-7 wherein the permeability agent exhibits at least about 5% of the permeability activity of bradykinin in a standard permeability assay.

11. The method of any one of claims 1-10 wherein the permeability agent is perfused through vasculature of the tissue prior to administration of the nucleic acid.
12. The method of any one of claims 1-11 wherein a low calcium ion concentration solution is perfused through vasculature of the tissue prior to administration of the nucleic acid.
13. The method of any one of claims 1-12 wherein low calcium ion concentration conditions are provided by perfusing through vasculature of the tissue a fluid having a calcium ion concentration of from about 40 $\mu\text{mol/L}$ to about 500 $\mu\text{mol/L}$.
14. The method of any one of claims 1-13 wherein the nucleic acid is administered as a viral vector in a solution at a concentration of about 1×10^8 pfu/ml or greater.
15. The method of any one of claims 1-14 wherein the nucleic acid is administered to a solid cell mass.
16. The method of any one of claims 1-14 wherein the nucleic acid is administered to a solid organ.
17. The method of claims 1-14 wherein the nucleic acid is administered to cells of heart, lung, kidney, testes, ovaries, skeletal muscle, kidneys, brain or spleen.
18. The method of any one of claims 1-16 wherein the tissue is cardiac tissue.
19. The method of any one of claims 1-16 wherein the tissue is liver tissue.
20. The method of any one of claims 1-19 wherein the tissue comprises malignant cells.
21. The method of any one of claims 1-19 wherein the nucleic acid is administered to a solid tumor.
22. The method of any one of claims 1-21 wherein the tissue is mammalian.
23. The method of any one of claims 1-22 wherein the nucleic acid is administered *ex vivo*.
24. The method of any one of claims 1-22 wherein the nucleic acid is administered *in vivo*.

-24-

25. The method of any one of claims 1-24 wherein the nucleic acid is administered to a human.

26. The method of any one of claims 1-24 wherein the nucleic acid is administered to livestock, poultry or dog or cat.

27. A method for expressing a gene product in malignant cells in targeted tissue, comprising:

treating the tissue to increase vascular permeability of exogenous nucleic acid;
and

administering exogenous nucleic acid to the tissue.

28. The method of claim 27 wherein the tissue is treated with a vascular permeability agent to increase vascular permeability.

29. The method of claims 27 or 28 wherein the nucleic acid is administered under low calcium ion concentration conditions.

30. The method of any one of claims 27-29 wherein the nucleic acid is administered under low calcium ion concentration conditions.

31. The method of any one of claims 27-29 wherein a solid tumor comprises the malignant cells.

32. The method of any one of claims 27-31 wherein the malignant cells are present in a lung, liver, prostate, brain, testes or ovaries of a subject.

33. The method of any one of claims 27-32 wherein the nucleic acid is administered by perfusion.

34. The method of any one of claims 27-33 wherein the nucleic acid is administered to a mammal.

35. The method of any one of claims 27-33 wherein the nucleic acid is administered to a primate.

36. The method of any one of claims 27-33 wherein the nucleic acid is administered to a human.

37. A method of providing, to a recipient subject, donor cells that comprise nucleic acid exogenous to the cells, comprising:

treating tissue comprising the donor cells to increase vascular permeability of exogenous nucleic acid;

administering nucleic acid to the tissue; and

introducing the donor cells into the recipient subject to express a gene product of the nucleic acid.

38. The method of claim 37 wherein an organ comprising the donor cells is transplanted into the recipient subject.

39. The method of claim 37 wherein the donor cells are swine cells or primate cells.

40. The method of any one of claims 37-39 wherein the tissue is treated with a vascular permeability agent to increase vascular permeability.

41. The method of any one of claims 37-40 wherein the tissue is treated with a low calcium ion concentration solution to increase vascular permeability.

42. The method of any one of claims 37-41 wherein the nucleic acid is administered under low calcium ion concentration conditions.

43. The method of any one of claims 37-42 wherein the gene product reduces recognition of the donor cells by the immune system of the recipient subject.

44. The method of any one of claims 37-43 wherein the donor cells are introduced into a mammal.

45. The method of any one of claims 37-43 wherein the donor cells are introduced into a mammal.

46. The method of any one of claims 37-43 wherein the donor cells are introduced into a human.

47. A pharmaceutical kit comprising:
a permeability agent that can increase vascular permeability of a subject; and
nucleic acid for administration to a subject.

48. The kit of claim 47 further comprising a solution having a calcium ion concentration of from about 40 $\mu\text{mol/L}$ to about 500 $\mu\text{mol/L}$.

49. The kit of claim 47 or 48 further comprising a device for delivery of the nucleic acid.

50. The kit of claim 49 wherein the delivery device is a catheter.

51. The kit of any one of claims 47-50 wherein the nucleic acid is present in the kit as a viral vector.

52. A treatment solution comprising:

-26-

a) a permeability agent that can increase vascular permeability of nucleic acid; and

b) nucleic acid.

53. The treatment solution of claim 52 wherein the solution has a low calcium ion concentration.

54. The treatment solution of claim 53 wherein the solution has a calcium ion concentration of from about 40 $\mu\text{mol/L}$ to about 500 $\mu\text{mol/L}$.

55. A treatment solution comprising nucleic acid in a fluid carrier and having a low calcium ion concentration.

56. The treatment solution of claim 55 wherein the solution has a calcium ion concentration of from about 40 $\mu\text{mol/L}$ to about 500 $\mu\text{mol/L}$.

57. A solution of any one of claims 37-41 wherein the solution is pharmaceutically acceptable.

58. A solution of any one of claims 52-57 wherein the solution comprises one or more therapeutic agents in addition to the nucleic acid.

59. A solution of any one of claims 52-54 and 57-58 wherein the solution comprises a plurality of permeability agents.

60. A solution of any one of claims 52-54 and 57-58 wherein the permeability agent is serotonin, bradykinin, platelet-activating factor, prostaglandin E_1 , histamine, vascular endothelium growth factor, zona occludens toxin, interleukin-2, plasma kinins, L-N-monomethyl arginine or L-N-nitro-arginine methyl ester.

1 / 3




FIG. 1A




FIG. 1B

2 / 3




FIG. 2




FIG. 3




FIG. 4




FIG. 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/21354

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A01N 43/04, 63/00; C12N 13/00, 5/00

US CL :514/44; 424/93.21; 435/455, 325

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44; 424/93.21; 435/455, 325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, CAS ONLINE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US 5,797,870 A (MARCH ET AL.) 25 August 1998, columns 3-6.	1-60
Y	US 5,308,622 A (CASSCELLS ET AL.) 03 May 1994, columns 3-8.	1-60
Y	US 5,661,133 A (LEIDEN ET AL.) 26 August 1997, columns 4-7.	1-60
Y	US 5,328,470 A (NABEL ET AL.) 12 July 1994, columns 11-17.	1-60
Y,P	US 5,776,427 A (THORPE ET AL.) 07 July 1998, columns 4-12	1-60
Y	US 5,240,848 A (KECK ET AL.) 31 August 1993, columns 7-9.	1-60

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
17 DECEMBER 1998Date of mailing of the international search report
26 JAN 1999Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230Authorized officer
DAVE NGUYEN
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/21354

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US 5,693,622 A (WOLFF ET AL.) 02 December 1997, columns 4-8.	1-60